The global downstream processing market size is expected to around USD 40.1billion by 2026, the market is projected to grow with 14.0% CAGR during the forecast timeframe. Rapid growth in bio application and bioprocess techniques is expected to bolster the global downstream processing market growth.
Rising investments in the growth of fermentation and bioprocess technologies to support the large scale production of biosimilar and biologics are anticipated to drive the growth of the market. Scope for the deployment of downstream processing technique for marketable production of biosimilars has been mountingdue to increasingneed for biosimilars.
Download Sample Copy of this report@ https://www.acumenresearchandconsulting.com/request-sample/912
Biopharmaceuticals are developing as novel paradigms for blockbuster medications and their sales are spiraling, despite their high costs. Consequently, owing to high financial profits offered by biopharmaceuticals, main pharma producers are progressively shifting their research & development activities to biopharma.
(CMOs) Contract manufacturing organizations are performingaimportant role in the development of the downstream processing market. A new biopharma plant, which is to be equipped with large stainless-steel bioreactors to produce high-volume biopharmaceuticals, necessitatesapproximately more than USD 250 million and a least lead time of four years. Consequently, start-ups, new market entrants, and some big pharma businessesincreasing their pipeline to biopharma switch to CMOs rather than building up their own production capacity.
Browse Full Report with Table Of Content, List of Table and Figures @
https://www.acumenresearchandconsulting.com/downstream-processing-market
Furthermore, a strong pipeline of biologics comprise ofmultispecific monoclonal antibodies, viral vectors, oligonucleotides, and peptides requires change of biopharma plants into multi-modality and multi-platform units. Though, most of these plants are still in mono-modality and mono-platform setup. Consequently, in this situation, contract manufacturing becomes an optimal choice for marketable production of biologics without growing manufacturing costs.
The global downstream processing market is segmented into four major segment named product, technique, application, and region. On the basis of product the downstream processing market is segmented into chromatography systems, filters, evaporators, centrifuges, dryers and others. On the basis of the technique the global downstream processing market is segmented into cell disruption, solid-liquid separation (filtration, centrifugation) concentration (evaporation, membrane filtration), and purification by chromatography and formulation. These solid-liquid separation are further bifurcated into filtration, and centrifugation, and theconcentration is also further segmented evaporation, and membrane filtration. On the basis of application, the downstream processing market is segmented into antibiotic production, hormone production, antibodies production, enzyme production, and vaccine production. On the basis of region the global downstream processing market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
North America captures the largest the global downstream processing market in 2018. The development of the region can be attributed to augmented focus of government bodies on the growth of the biotechnology industry, increasing healthcare expenditure, and occurrence of adequate infrastructure for development and growth of bioprocessing industries.
Due to recent progressions, there is a considerableincrease in sales of biotechnology products in the region. Consequently, continual innovations in the biotechnology sector are possible to deliverplentydevelopment opportunities to the regional market during the forecast timeframe.
Asia Pacific is captures the fastest growth during the forecasted time frame due to constant efforts undertaken to reinforce the genomic landscape andbiotechnology infrastructure in nations such as ChinaandIndia. In current times, the region has witnessed beginning of speedy analytical methods that deliver in-process control and provision evaluation of process design. Also this, launching of vendors and supply chains for bioprocessing consumables and equipment that are at par with the highest international standards, across major emergingnations, is predictable to contribute to the growth of the market in the APAC region.
The key players catering to the global downstream processing market areGeneral Electric Company (GE Healthcare),Thermo Fisher Scientific Inc., Merck KGaA (Merck Millipore), Sartorius Stedim Biotech S.A., and Danaher Corporation. Some other players catering to the market are Dover Corporation (CPC (Colder Products Co.)), Repligen, BoehringerIngelheim International GmbH, 3M Company, Eppendorf AG, Corning Corporation, Ashai Kasei, Lonza Group Ltd, and Ferner PLC.These players are investing huge capital to innovate the product portfolio as the competition in the market is increasing with rapid pace. Also, with changing technology the need for better infrastructures are increasing, so cater the need of the customers, players are continuously innovating new products.